An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
NCT ID: NCT01357668
Last Updated: 2025-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
800 participants
OBSERVATIONAL
2013-01-30
2029-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long Term Experience With Abatacept in Routine Clinical Practice
NCT02109666
Long-term Experience With Abatacept SC in Routine Clinical Practice
NCT02090556
Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin
NCT03466814
Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan
NCT02335606
A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis
NCT03457792
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with JIA who are treated with Abatacept
Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \< 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
* Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial
* Parent or legally acceptable representative willing to participate in the study and sign the informed consent
Exclusion Criteria
* Prior malignancies if the patient has not been malignancy free for at least 5 years.
* Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study
* Known poor compliance with clinic visits (based on physician judgment).
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0060
Little Rock, Arkansas, United States
Local Institution - 0001
Princeton, New Jersey, United States
Local Institution - 0059
Cincinnati, Ohio, United States
Local Institution - 0025
Bregenz, , Austria
Local Institution - 0002
Innsbruck, , Austria
Local Institution - 0032
Vienna, , Austria
Local Institution - 0010
Botucatu, São Paulo, Brazil
Local Institution - 0026
Campinas, São Paulo, Brazil
Local Institution - 0028
São Paulo, São Paulo, Brazil
Local Institution - 0027
Rio de Janeiro, , Brazil
Local Institution - 0029
Calgary, Alberta, Canada
Local Institution - 0011
Montreal, Quebec, Canada
Local Institution - 0035
Aarhus, Central Jutland, Denmark
Local Institution - 0012
Copenhagen, , Denmark
Local Institution - 0040
Clermont-Ferrand, Puy-de-Dôme, France
Local Institution - 0005
Paris, , France
Local Institution - 0041
Toulouse, , France
Local Institution - 0003
Bad Bramstedt, , Germany
Local Institution - 0030
Berlin, , Germany
Local Institution - 0034
Freiburg im Breisgau, , Germany
Local Institution - 0031
Hamburg, , Germany
Local Institution - 0033
Heidelberg, , Germany
Local Institution - 0016
Thessaloniki, , Greece
Local Institution - 0017
Budapest, , Hungary
Local Institution - 0014
Jerusalem, , Israel
Local Institution - 0042
Florence, , Italy
Local Institution - 0015
Genova, , Italy
Local Institution - 0043
Naples, , Italy
Local Institution - 0045
Napoli, , Italy
Local Institution - 0044
Padua, , Italy
Local Institution - 0046
Trento, , Italy
Local Institution - 0018
Riga, , Latvia
Local Institution - 0006
Guadalajara, Jalisco, Mexico
Local Institution - 0047
Rotterdam, , Netherlands
Local Institution - 0019
Utrecht, , Netherlands
Local Institution - 0048
Tromsø, , Norway
Local Institution - 0049
Trondheim, , Norway
Local Institution - 0007
Lima, , Peru
Local Institution - 0050
Lima, , Peru
Local Institution - 0020
Lisbon, , Portugal
Local Institution - 0023
Bayamón, , Puerto Rico
Local Institution - 0056
Bayamón, , Puerto Rico
Local Institution - 0021
Cluj-Napoca, , Romania
Local Institution - 0051
Moscow, , Russia
Local Institution
Moscow, , Russia
Local Institution - 0053
Saint Petersburg, , Russia
Local Institution - 0052
Saratov, , Russia
Local Institution - 0055
Jeddah, , Saudi Arabia
Local Institution - 0024
Riyadh, , Saudi Arabia
Local Institution - 0022
Piešťany, , Slovakia
Local Institution - 0009
Pretoria, Gauteng, South Africa
Local Institution - 0057
Panorama, Cape Town, Western Cape, South Africa
Local Institution - 0058
Pretoria, , South Africa
Local Institution - 0036
Sant Joan Despí, Barcelona, Spain
Local Institution - 0004
Barcelona, , Spain
Local Institution - 0038
Madrid, , Spain
Local Institution - 0037
Murcia, , Spain
Local Institution - 0039
Valencia, , Spain
Local Institution - 0013
Bristol, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lovell DJ, Tzaribachev N, Henrickson M, Simonini G, Griffin TA, Alexeeva E, Bohnsack JF, Zeft A, Horneff G, Vehe RK, Stanevica V, Tarvin S, Trachana M, Del Rio AQ, Huber AM, Kietz D, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Simon TA, Martini A, Brunner HI, Ruperto N; for PRINTO and the Pediatric Rheumatology Collaborative Study Group (PRCSG) section sign. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology (Oxford). 2024 Sep 1;63(SI2):SI195-SI206. doi: 10.1093/rheumatology/keae025.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM101-240
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.